<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) occurs as a primary entity or in association with <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, or medications </plain></SENT>
<SENT sid="1" pm="."><plain>Conventional treatment for APS-associated <z:mp ids='MP_0005048'>thrombosis</z:mp> involves the use of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> such as aspirin, <z:chebi fb="5" ids="28304">heparin</z:chebi>, and <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Alternative treatment options are limited </plain></SENT>
<SENT sid="3" pm="."><plain>We report on a patient with APS who failed conventional therapy but had clinical improvement and a decline in anticardiolipin (aCL) antibody titers during treatment with monthly intravenous immunoglobulin (IVIg) </plain></SENT>
<SENT sid="4" pm="."><plain>Anticardiolipin antibodies IgG, IgA, and IgM were measured before initiating IVIg and before each subsequent infusion of IVIg </plain></SENT>
<SENT sid="5" pm="."><plain>The patient was also evaluated for the presence of thromboses during the treatment period </plain></SENT>
<SENT sid="6" pm="."><plain>IgG and IgA aCL levels were elevated initially, and there was a significant decrease in anticardiolipin IgG and IgA levels during treatment without further episodes of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>IVIg may be an alternative therapy for <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> in the <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
</text></document>